PofoliaPofolia ile paylaşıldı

New England Journal of Medicine· 2016Q1

İleri Evre Baş ve Boyun Kanserinde PET-BT Gözetimi ve Boyun Diseksiyonunun Karşılaştırılması

PET-CT Surveillance versus Neck Dissection in Advanced Head and Neck Cancer

Hisham Mehanna, Wai‐Lup Wong, Christopher C. McConkey, Joy K Rahman ve diğerleri

Kısa özet

PET-BT güdümlü takip, ileri evre baş ve boyun kanseri için planlanmış boyun diseksiyonuna göre daha az invazivdir, daha az ameliyata yol açar ve maliyet açısından daha avantajlıdır.

Yapay zekâ ile başlık ve abstract'tan üretildi; tam metin okunmaz.

Ana noktalar

  • PET-BT güdümlü takip, ileri evre baş ve boyun kanseri için planlanmış boyun diseksiyonuna göre non-inferior bulunmuştur.
  • Takip grubunda 2 yıllık genel sağkalım oranı %84.9, planlanmış cerrahi grubunda ise %81.5 olarak saptanmıştır.
  • Gözetim, benzer komplikasyon oranlarıyla anlamlı derecede daha az boyun diseksiyonu ameliyatına (54'e karşılık 221) neden olmuştur.
  • PET-BT güdümlü takip, kişi başı 1.492 £ (yaklaşık 2.190 ABD Doları) tasarruf sağlayarak daha maliyet etkin olmuştur.

Yapay zekâ ile başlık ve abstract'tan üretildi; tam metin okunmaz.

Özet (abstract)

BACKGROUND: The role of image-guided surveillance as compared with planned neck dissection in the treatment of patients with squamous-cell carcinoma of the head and neck who have advanced nodal disease (stage N2 or N3) and who have received chemoradiotherapy for primary treatment is a matter of debate. METHODS: In this prospective, randomized, controlled trial, we assessed the noninferiority of positron-emission tomography-computed tomography (PET-CT)-guided surveillance (performed 12 weeks after the end of chemoradiotherapy, with neck dissection performed only if PET-CT showed an incomplete or equivocal response) to planned neck dissection in patients with stage N2 or N3 disease. The primary end point was overall survival. RESULTS: From 2007 through 2012, we recruited 564 patients (282 patients in the planned-surgery group and 282 patients in the surveillance group) from 37 centers in the United Kingdom. Among these patients, 17% had nodal stage N2a disease and 61% had stage N2b disease. A total of 84% of the patients had oropharyngeal cancer, and 75% had tumor specimens that stained positive for the p16 protein, an indicator that human papillomavirus had a role in the causation of the cancer. The median follow-up was 36 months. PET-CT-guided surveillance resulted in fewer neck dissections than did planned dissection surgery (54 vs. 221); rates of surgical complications were similar in the two groups (42% and 38%, respectively). The 2-year overall survival rate was 84.9% (95% confidence interval [CI], 80.7 to 89.1) in the surveillance group and 81.5% (95% CI, 76.9 to 86.3) in the planned-surgery group. The hazard ratio for death slightly favored PET-CT-guided surveillance and indicated noninferiority (upper boundary of the 95% CI for the hazard ratio, <1.50; P=0.004). There was no significant difference between the groups with respect to p16 expression. Quality of life was similar in the two groups. PET-CT-guided surveillance, as compared with neck dissection, resulted in savings of £1,492 (approximately $2,190 in U.S. dollars) per person over the duration of the trial. CONCLUSIONS: Survival was similar among patients who underwent PET-CT-guided surveillance and those who underwent planned neck dissection, but surveillance resulted in considerably fewer operations and it was more cost-effective. (Funded by the National Institute for Health Research Health Technology Assessment Programme and Cancer Research UK; PET-NECK Current Controlled Trials number, ISRCTN13735240.).

Yazarların özeti; kaynağından alınmıştır. New England Journal of Medicine, 2016 · DOI ↗

ÇıkarımlarPremium
Makaleye SorÜcretsiz hesapla

Ücretsiz hesapla devam et

Makaleye Sor ile bu makaleye günde 3 soru ücretsiz; makaleyi kaydet, kaynakçasını al, ilgi alanına göre her gün yeni özetler. Çıkarımlar Premium.

Web'de ücretsiz devam et

Google ya da Apple hesabınla giriş; kart istemez. Bu makaleye geri dönersin.

Telefonda:

Alan: Kulak Burun Boğaz

OtorhinolaryngologyMedicine